These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
517 related articles for article (PubMed ID: 20168271)
21. Intravitreal bevacizumab for the treatment of choroidal neovascularization secondary to angioid streaks: one year of follow-up. El Matri L; Kort F; Bouraoui R; Karim B; Chebil A; Chaker N Acta Ophthalmol; 2011 Nov; 89(7):641-6. PubMed ID: 21155980 [TBL] [Abstract][Full Text] [Related]
22. Results of one-year follow-up examinations after intravitreal bevacizumab administration for chronic central serous chorioretinopathy. Inoue M; Kadonosono K; Watanabe Y; Kobayashi S; Yamane S; Arakawa A Ophthalmologica; 2011; 225(1):37-40. PubMed ID: 20693820 [TBL] [Abstract][Full Text] [Related]
28. Prognostic factors for visual outcome after intravitreal anti-VEGF injection for naive myopic choroidal neovascularization. Yoon JU; Kim YM; Lee SJ; Byun YJ; Koh HJ Retina; 2012 May; 32(5):949-55. PubMed ID: 22534553 [TBL] [Abstract][Full Text] [Related]
29. Intravitreal bevacizumab for exudative branching vascular networks in polypoidal choroidal vasculopathy. Wakabayashi T; Gomi F; Sawa M; Tsujikawa M; Nishida K Br J Ophthalmol; 2012 Mar; 96(3):394-9. PubMed ID: 21719568 [TBL] [Abstract][Full Text] [Related]
30. Intravitreal bevacizumab (avastin) for choroidal neovascularization secondary to central serous chorioretinopathy, secondary to punctate inner choroidopathy, or of idiopathic origin. Chan WM; Lai TY; Liu DT; Lam DS Am J Ophthalmol; 2007 Jun; 143(6):977-983. PubMed ID: 17459318 [TBL] [Abstract][Full Text] [Related]
35. Intravitreal bevacizumab for subfoveal choroidal neovascularization in age-related macular degeneration at twenty-four months: the Pan-American Collaborative Retina Study. Arevalo JF; Sánchez JG; Wu L; Berrocal MH; Alezzandrini AA; Restrepo N; Maia M; Farah ME; Brito M; Díaz-Llopis M; Rodríguez FJ; Reategui G; Iturralde-Iraola J; Udaondo-Mirete P; Ophthalmology; 2010 Oct; 117(10):1974-81, 1981.e1. PubMed ID: 20569989 [TBL] [Abstract][Full Text] [Related]
36. Effect of intravitreal bevacizumab (Avastin) in neovascular age-related macular degeneration using a treatment regimen based on optical coherence tomography: 6- and 12-month results. Leydolt C; Michels S; Prager F; Garhoefer G; Georgopoulos M; Polak K; Schmidt-Erfurth U Acta Ophthalmol; 2010 Aug; 88(5):594-600. PubMed ID: 19485959 [TBL] [Abstract][Full Text] [Related]
37. Effects of ranibizumab in patients with subfoveal choroidal neovascularization attributable to age-related macular degeneration. Rothenbuehler SP; Waeber D; Brinkmann CK; Wolf S; Wolf-Schnurrbusch UE Am J Ophthalmol; 2009 May; 147(5):831-7. PubMed ID: 19217019 [TBL] [Abstract][Full Text] [Related]
38. Different dosing of intravitreal bevacizumab for choroidal neovascularization because of pathologic myopia. Wakabayashi T; Ikuno Y; Gomi F Retina; 2011 May; 31(5):880-6. PubMed ID: 21242860 [TBL] [Abstract][Full Text] [Related]
39. Long-term outcomes of intravitreal antivascular endothelial growth factor therapy for the management of choroidal neovascularization in pseudoxanthoma elasticum. Myung JS; Bhatnagar P; Spaide RF; Klancnik JM; Cooney MJ; Yannuzzi LA; Freund KB Retina; 2010 May; 30(5):748-55. PubMed ID: 19996818 [TBL] [Abstract][Full Text] [Related]